Immunyx Pharma is a drug development company focused on modulating neutrophil function to treat disease.

Using the company's platform technology to specifically manipulate neutrophils using a targeted nanoparticle, Immunyx will bring new therapies to several diseases where neutrophil treatment could advance a cure.

Immunyx Pharma's neutrophil-targeting technology is based on years of basic and translational research by professors Zvika Granot and Zvi Fridlender at the Hebrew University.